Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
NASA probe captures stunning photos of Earth and moon on the way to infamous asteroid Apophis - 2Space station changes command, setting stage for Crew 11 departure
- 3What's your #1 tone
- 4What are parents to do as doctors clash with Trump administration over vaccines?
- 5Find the Interesting Universe of Computerized reasoning: the Capability of man-made intelligence
- 6 Famous Urban communities for Shopping on the planet
- Holiday weather forecast: Where travelers can expect a wintry mix, flooding and record warmth across the U.S.
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Human evolution’s biggest mystery has started to unravel. How 2025 tipped the scales
- Colleges say foreign students feel 'unwelcome' in the U.S. amid big drop in international enrollment, new survey finds
- Amy Poehler's podcast is a hit. It's also a Trojan horse for talking about women and aging.
- Father and son spending Christmas together after health scares
- Early Thanksgiving week forecast: Where Americans can expect cold, rain and snow for the holiday
- SUVs Known for Their Looks As opposed to Their Capacity
